Cyclerion Therapeutics (NASDAQ:CYCN) Announces Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) announced its quarterly earnings results on Monday. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.19, FiscalAI reports. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.10 million.

Cyclerion Therapeutics Trading Down 4.0%

NASDAQ CYCN opened at $1.45 on Tuesday. The stock has a market capitalization of $5.68 million, a price-to-earnings ratio of -1.93 and a beta of 0.94. The stock has a 50-day moving average of $1.38 and a 200 day moving average of $1.69. Cyclerion Therapeutics has a twelve month low of $1.03 and a twelve month high of $3.79.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.